ARGELIA GONZALEZ: Open Payments
NPI 1053051367 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,012 in 97 payments from 20 companies in 2025. Trend: 2023 $702 · 2024 $1,631 · 2025 $3,012
Food & beverage: $3,012
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $538 |
| AstraZeneca Pharmaceuticals LP | 18 | $506 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $378 |
| Amgen Inc. | 11 | $260 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $163 |
| GENZYME CORPORATION | 1 | $146 |
| ABBVIE INC. | 6 | $137 |
| Dexcom, Inc. | 1 | $122 |
| Lilly USA, LLC | 7 | $120 |
| Exact Sciences Corporation | 6 | $112 |
Products named: Kerendia, Wegovy, AIRSUPRA, Ozempic, FARXIGA, XIFAXAN, REPATHA, FABRAZYME.
Industry payments across TX — which companies pay providers there.
